Literature DB >> 2926877

Use of amitriptyline in the treatment of interstitial cystitis.

P M Hanno1, J Buehler, A J Wein.   

Abstract

A total of 25 patients with interstitial cystitis who had failed standard therapy with hydrodistension of the bladder during anesthesia and intravesical dimethyl sulfoxide instillation underwent treatment with the tricyclic antidepressant amitriptyline. The initial dosage of 25 mg. before bed was increased gradually during a 3-week period to 75 mg. at bedtime. Of the patients 20 were able to tolerate the medication for a minimum of 3 weeks and could be evaluated for response. A significant improvement was noted in pain and daytime frequency. Of 9 patients 8 experienced relief of dyspareunia and 11 of 19 reported diminished urinary urgency. Eight patients have experienced virtual total remission of symptoms and have been on the drug for 4 to 28 months. It appears reasonable to consider the use of amitriptyline in patients with interstitial cystitis refractory to standard therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2926877     DOI: 10.1016/s0022-5347(17)41029-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Extracorporeal shock wave therapy ameliorates cyclophosphamide-induced rat acute interstitial cystitis though inhibiting inflammation and oxidative stress-in vitro and in vivo experiment studies.

Authors:  Yen-Ta Chen; Chih-Chao Yang; Cheuk-Kwan Sun; Hsin-Ju Chiang; Yi-Ling Chen; Pei-Hsun Sung; Yen-Yi Zhen; Tein-Hung Huang; Chia-Lo Chang; Hong-Hwa Chen; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

2.  CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome.

Authors:  Ashley Cox; Nicole Golda; Genevieve Nadeau; J Curtis Nickel; Lesley Carr; Jacques Corcos; Joel Teichman
Journal:  Can Urol Assoc J       Date:  2016-05-12       Impact factor: 1.862

Review 3.  Painful bladder syndrome: an update and review of current management strategies.

Authors:  Anthony J Dyer; Christian O Twiss
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

4.  Electromotive drug administration of lidocaine and dexamethasone followed by cystodistension in women with interstitial cystitis.

Authors:  A Rosamilia; P L Dwyer; J Gibson
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

5.  Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome.

Authors:  Harris E Foster; Philip M Hanno; J Curtis Nickel; Christopher K Payne; Robert D Mayer; David A Burks; Claire C Yang; Toby C Chai; Karl J Kreder; Kenneth M Peters; Emily S Lukacz; Mary P FitzGerald; Liyi Cen; J Richard Landis; Kathleen J Propert; Wei Yang; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2010-03-29       Impact factor: 7.450

6.  Role of inflammation in bladder function and interstitial cystitis.

Authors:  Sonal Grover; Abhishek Srivastava; Richard Lee; Ashutosh K Tewari; Alexis E Te
Journal:  Ther Adv Urol       Date:  2011-02

7.  The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis.

Authors:  Gou Kaneko; Koshiro Nishimoto; Yujiro Ito; Atsushi Uchida
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

Review 8.  Treatment approaches for painful bladder syndrome/interstitial cystitis.

Authors:  Theoharis C Theoharides
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review.

Authors:  Jordan Dimitrakov; Kurt Kroenke; William D Steers; Charles Berde; David Zurakowski; Michael R Freeman; Jeffrey L Jackson
Journal:  Arch Intern Med       Date:  2007-10-08

10.  Antidepressant drugs for chronic urological pelvic pain: an evidence-based review.

Authors:  Christos Papandreou; Petros Skapinakis; Dimitrios Giannakis; Nikolaos Sofikitis; Venetsanos Mavreas
Journal:  Adv Urol       Date:  2010-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.